How big is the global pharmaceuticals market?
Novel active substance launches worldwide stood at 79 in 2025 (IQVIA).
Pharmaceuticals statistics
572 verified statistics on the pharmaceuticals industry, drawn from 22 primary sources and covering 17 regions. Every figure links to the report it came from.
Data points
572
Primary sources
22
Indicators
397
Regions
17
Period
1999–2035
At a glance
First-in-class drug approvals
The lead series for this industry. Forecasts are dashed with hollow markers. Download the underlying rows from the data table below.
First-in-class drug approvals
China, 2022 to 2025
Source: NMPA, NHSA · CC BY 4.0 · statorigin.org
The short version
Key takeaways
Each line is a complete, citable statement. Use the copy button to take the citation with the number.
- Novel active substance launches worldwide stood at 79 in 2025 (IQVIA). IQVIA ↗
- Cancer medicine spending worldwide totalled 252 billion USD in 2024 (IQVIA). IQVIA ↗
- Cell and gene therapy spending worldwide totalled 5.9 billion USD in 2023 (IQVIA). IQVIA ↗
- Medicine spending worldwide totalled 1.6 trillion USD in 2023 (IQVIA). IQVIA ↗
- Pharmaceutical R&D GDP contribution worldwide stood at 227 billion USD in 2022 (IFPMA). IFPMA ↗ T2 National
- Pharmaceutical R&D employment worldwide stood at 1 million in 2022 (IFPMA). IFPMA ↗ T2 National
- Cell and gene therapy venture capital and public funding deal value worldwide stood at 3.4 billion USD in 2023 (IQVIA). IQVIA ↗
- IQVIA projects pharmerging markets medicine spending growth worldwide at 121 billion USD in 2026–2030. IQVIA ↗
- Average cost to develop a new medicine worldwide averaged 2.6 billion USD at end of 2025 (PhRMA). PhRMA ↗ T2 National
- Medicines in clinical development worldwide stood at 12,900 in 2025 (IFPMA). IFPMA ↗ T2 National
- Pharmaceutical industry direct employment worldwide stood at 7.8 million in 2022 (IFPMA). IFPMA ↗ T2 National
- Pharmaceutical and medicine manufacturing net sales in United States totalled 685,744 million USD in 2022 (NCSES). NCSES ↗ T1 Official
- IQVIA projects high GDP developed countries medicine spending growth worldwide at 155.1 billion USD in 2025–2030. IQVIA ↗
- Cell and gene therapy spending growth rate worldwide came in at 38% in 2023 (IQVIA). IQVIA ↗
Answered from the data
Common questions
Which country leads in pharmaceuticals?
United States recorded the highest novel active substance launches at 53 in 2025 (IQVIA).
How fast is the pharmaceuticals market growing?
Inter-trial interval increase worldwide came in at 3 months in 2025 (IQVIA).
What are the key market share figures for pharmaceuticals?
Business earnings per share growth came in at 31.4% in Q2 2026 (Sanofi).
What is the forecast for pharmaceuticals?
IQVIA projects additional novel active substance launches worldwide at 375 in 2026–2030.
Where does this pharmaceuticals data come from?
Every figure on this page traces to a primary source: 22 organisations publish the underlying data, and the dataset spans 1999 to 2035. The full source table lists each report, its publication date and the original link.
How often is this page updated?
The dataset was last verified on 17 September 2026. Annual series are refreshed when the publisher releases a new edition; corrections are accepted at any time and answered within 48 hours.
Visualised
Pharmaceuticals charts
Rendered as plain SVG, so they work with JavaScript disabled and can be embedded anywhere. Forecasts are drawn dashed, with hollow markers.
Health sector research and development investment growth rate by country
Latest available period per country
View the underlying data
| Category | Source | Type | Value |
|---|---|---|---|
| Japan | European Commission | Actual | 9.1% |
| United States | European Commission | Actual | 7.1% |
| China | European Commission | Actual | 0.1% |
Source: European Commission · CC BY 4.0 · statorigin.org
Clinical trial registrations
China, 2021 to 2025
Source: State Council, NHSA · CC BY 4.0 · statorigin.org
The complete table
All pharmaceuticals data points
Grouped by indicator. Every row links to its own page with the full source, quote and citation. The CSV includes provenance columns so each downloaded row stays citable.
572 data points across 397 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
IndicatorRegionPeriodValueSourceType
Additional novel active substance launchesGlobal2026–2030375IQVIA2030forecast→
Alzheimer's disease innovative drug clinical trial approvals (multi-year total)China2023–20248NMPAT12024actual→
Annual net sales growth guidance at constant exchange ratesGlobal202610%SanofiT22026forecast→
Antibody-drug conjugate approvalsChina20253DIAT22025actual→
Approved Class 1 innovative drugsChina202576NHSAT12025actual→
Approved Class 1 innovative drugs (half year)Chinaas of 30 Jun 202638NHSAT12026actual→
Approved drug marketing registration applications (half year)Chinaas of 30 Jun 20262,318NHSAT12026actual→
Approved immunotherapy drugs (multi-year total)United States2010–202530PhRMAT22025actual→
Approved innovative drugs designated as breakthrough therapies +1 more China202413State CouncilT12024actual→
Approved innovative drugs growth rateChina202558.3%MOFCOMT12025actual→
Approved innovative drugs with new targets or mechanismsChina202511NHSAT12025actual→
Approved innovative drugs with new targets or mechanisms (half year)Chinaas of 30 Jun 202611NHSAT12026actual→
Approved novel drugs in breakthrough therapy programsChina202413NMPAT12024actual→
Average annual growth in cancer medicine spendingGlobal2020–202411.9%IQVIA2024actual→
Average annual novel active substance launchesGlobal2026–203075IQVIA2030forecast→
Average annual oncology novel active substance launches (multi-year total) +1 more Global2020–202426IQVIA2024actual→
Average cost to develop a new medicineGlobalend of 20252.6 billion USDPhRMAT22025estimate→
Beneficiaries of negotiated reimbursement drugs +1 more Chinaas of 31 Oct 2024830 millionNHSAT12024actual→
- Chinaas of 31 Oct 2024830 millionState CouncilT12024actual→
Bioequivalence trialsChina20252,218NHSAT12025actual→
Bioequivalence trials shareChina202542.5%NHSAT12025actual→
Biologic therapy approvalsChina202540DIAT22025actual→
Biopharma, biotech and AI companies countUnited Kingdomas of 28 Jul 2026470GSKT22026actual→
Biopharmaceutical R&D expenditure (multi-year total)United States2015–2024900 billion USDPhRMAT22024actual→
Biosimilar biological product approvalsUnited States202418FDAT12024actual→
Bispecific antibody approvalsChina20254DIAT22025actual→
Botanical drug products approved as prescription drugsUnited Statesas of 3 Sep 20264FDAT12026actual→
Branded medicines sales clawback capUnited Kingdomas of 8 Sep 202615%ABPIT22026actual→
Breast cancer drug approvalsChina20259DIAT22025actual→
Business earnings per shareGlobalQ2 20262.09 EURSanofiT22026actual→
Business earnings per share growthGlobalQ2 202631.4%SanofiT22026actual→
Business EPS growth at constant exchange ratesGlobalQ2 202633.3%SanofiT22026actual→
Cancer medicine spending +1 more Global2024252 billion USDIQVIA2024actual→
Cell and gene therapy clinical trial starts +1 more Global2023631IQVIA2023actual→
Cell and gene therapy reimbursement rate +1 more European UnionApril 202342%IQVIA2023actual→
- European Unionas of 1 Apr 202342%IQVIA2023actual→
Cell and gene therapy share of medicine spendingGlobal20230.4%IQVIA2023actual→
Cell and gene therapy spendingGlobal20235.9 billion USDIQVIA2023actual→
Cell and gene therapy spending average annual growth rateGlobal2019–202365%IQVIA2023actual→
Cell and gene therapy spending growth rateGlobal202338%IQVIA2023actual→
Cell and gene therapy spending share by geography +1 more Global202338%IQVIA2023actual→
- United States202362%IQVIA2023actual→
Cell and gene therapy spending year-over-year growthGlobal202338%IQVIA2023actual→
Cell and gene therapy venture capital and public funding deal count +3 more Global2023100IQVIA2023estimate→
Cell and gene therapy venture capital and public funding deal valueGlobal20233.4 billion USDIQVIA2023actual→
Cell and gene therapy venture funding deal count year-over-year change +2 more Global202319%IQVIA2023actual→
Cell therapy approvalsChina20253DIAT22025actual→
Centralized procurement drugs added to national reimbursement drug listChinaas of 28 Nov 20242NHSAT12024actual→
Chemically synthesized share of new medicine launchesGermany202557%VFAT22025actual→
Class 1 innovative drug clinical trialsChina20252,171NHSAT12025actual→
Class 1 innovative drug clinical trials growth rateChina20254.1%NHSAT12025actual→
Class 1 innovative drug clinical trials shareChina202572.4%NHSAT12025actual→
Clinical development drug pipeline assets countGlobalas of 28 Jul 202662GSKT22026actual→
Clinical development regulatory approval rateUnited Statesend of 202512%PhRMAT22025estimate→
Clinical trial country use share +9 more European Union202527%IQVIA2025actual→
- European Union202527%IQVIA2025actual→
- European Union202325%IQVIA2023actual→
- North America202323%IQVIA2023actual→
- China202315%IQVIA2023actual→
- China2021–202313%IQVIA2023actual→
- United States2021–202316%IQVIA2023actual→
- European Union201932%IQVIA2019actual→
- North America201919%IQVIA2019actual→
- China201910%IQVIA2019actual→
Clinical trial country use share change +2 more European Union2019–2023-21%IQVIA2023actual→
Clinical trial country uses growth rateEuropean Union2019–2025-17%IQVIA2025actual→
Clinical trial country utilization growth rateEuropean Union2019–2025-17%IQVIA2025actual→
Clinical trial enrollment duration growthGlobal2019–202326%IQVIA2023actual→
Clinical trial enrollment duration increase (multi-year total)Global2019–20236 monthsIQVIA2023actual→
Clinical trial patient recruitment changeUnited Kingdom2022–2025-25%ABPIT22025actual→
Clinical trial registrations +6 more Asia-Pacific202531,097WHOT12025actual→
- Africa2025822WHOT12025actual→
- China20255,215NHSAT12025actual→
- Asia-Pacific202427,172WHOT12024actual→
- China20234,300State CouncilT12023actual→
- China20223,410State CouncilT12022actual→
- China20213,358State CouncilT12021actual→
Clinical trial registrations growth rateChina20256.4%NHSAT12025actual→
Clinical trials recruitment setup timeliness rateUnited Kingdomas of 8 Sep 202658%ABPIT22026actual→
Clinical trials regulatory approval timeliness rateUnited Kingdomas of 8 Sep 202698%ABPIT22026actual→
Commercial insurance patient out-of-pocket medicine cost growth rateUnited States20255%IQVIA2025actual→
Commercial insurance share of patient out-of-pocket medicine costsUnited States202552%IQVIA2025actual→
Common new active substance approvals across major regulatory authorities (multi-year total) +1 more Global2021–202552CIRS2025actual→
Company countries of operationGlobalas of 20 Aug 2026150RocheT22026actual→
Company operating locationsUnited Statesas of 20 Aug 202624RocheT22026actual→
Compound annual net medicine spending growthUnited States2020–20259.3%IQVIA2025actual→
Contact lens wearersGlobalas of 10 Sep 2026140 millionJ&JT22026actual→
Conventional medicine approvalsChina202580DIAT22025actual→
Core diluted earnings per share +1 more GlobalQ1 202610.8 CHFRocheT22026actual→
Core diluted earnings per share growth at constant exchange ratesGlobalQ1 20269%RocheT22026actual→
Core diluted earnings per share growth in Swiss francsGlobalQ1 2026-2%RocheT22026actual→
Core earnings per share growth at constant exchange ratesGlobalQ1 20269%RocheT22026actual→
Core earnings per share growth in Swiss francsGlobalQ1 2026-2%RocheT22026actual→
Core operating profit +1 more GlobalQ1 202611.9 billion CHFRocheT22026actual→
Core operating profit (half year)Globalas of 30 Jun 202611,856 million CHFRocheT22026actual→
Core operating profit growth (quarterly)GlobalQ2 20267%GSKT22026actual→
Core operating profit growth at constant exchange ratesGlobalQ1 202610%RocheT22026actual→
Core operating profit growth in Swiss francsGlobalQ1 2026-1%RocheT22026actual→
Countries with drug approvalGlobalas of 10 Sep 202690RocheT22026actual→
COVID-19 vaccines and therapeutics spending declineUnited States20254 billion USDIQVIA2025actual→
Cumulative biopharmaceutical R&D expenditureUnited States2000–20251 trillion USDPhRMAT22025actual→
Cumulative biosimilar approvalsUnited States2015–202460FDAT12024actual→
Cumulative cell and gene therapy launchesGlobalend of 202376IQVIA2023actual→
Cumulative drug approval applications under priority reviewChinaend of 2024496State CouncilT12024actual→
Cumulative drug approval applications under priority review (annual)China2020–2024496NMPAT12024actual→
Cumulative drugs added via negotiation in reimbursement drug listChinaas of 28 Nov 2024530NHSAT12024actual→
Cumulative drugs removed from reimbursement drug listChinaas of 28 Nov 2024438NHSAT12024actual→
Cumulative five-year novel active substance launches +3 more Global2021–2025388IQVIA2025actual→
- Global2021–2025388IQVIA2025actual→
- United States2021–2025270IQVIA2025actual→
- United States2021–2025270IQVIA2025actual→
Cumulative five-year novel active substance launches excluding COVID-19 vaccines and therapeuticsGlobal2021–2025369IQVIA2025actual→
Cumulative health insurance fund payout for negotiated medicinesChinaas of 31 Oct 2024350 billion CNYState CouncilT12024actual→
Cumulative negotiated drug sales during agreement periodChinaas of 31 Oct 2024510 billion CNYState CouncilT12024actual→
Cumulative newly added drugs in reimbursement drug listChinaas of 28 Nov 2024835NHSAT12024actual→
Cumulative oncology novel active substance launches +2 more Global2020–2024132IQVIA2024actual→
Cumulative patient burden reduction from negotiated drugsChinaas of 31 Oct 2024880 billion CNYNHSAT12024actual→
Domestic contribution to new entrant increaseChina202581%DIAT22025actual→
Domestic developer drug approvalsChina202563DIAT22025actual→
Domestic developer share of drug approvalsChina202552%DIAT22025actual→
Domestic first-in-class drug approvals +1 more China20254NHSAT12025actual→
Domestic innovative biological product approvals +1 more China202521NHSAT12025actual→
Domestic innovative chemical drug approvals +1 more China202538NHSAT12025actual→
Domestic innovative drug approvals (half year) +1 more Chinaas of 30 Jun 202631State CouncilT12026actual→
Domestic share of approved innovative biological products +1 more China202591.3%NHSAT12025actual→
Domestic share of approved innovative chemical drugs +1 more China202580.8%NHSAT12025actual→
Domestic-only oncology novel active substance launches (multi-year total)China2020–202445IQVIA2024actual→
Drug approval applications completed under priority review +1 more China2024110State CouncilT12024actual→
Drug clinical trialsChina20255,000NHSAT12025actual→
Drugs in commercial health insurance innovative drug catalog +1 more Chinaas of 7 Dec 202519SCIOT12025actual→
- Chinaas of 7 Dec 202519State CouncilT12025actual→
Drugs removed from national reimbursement drug list +1 more China202529NHSAT12025actual→
- China202443State CouncilT12024actual→
Drugs removed from national reimbursement drug list (year to date)Chinaas of 28 Nov 202443NHSAT12024actual→
Dupixent salesGlobalQ2 20265.2 billion EURSanofiT22026actual→
Dupixent sales (annual)Global203025 billion EURSanofiT22026forecast→
Dupixent sales growthGlobalQ2 202637.6%SanofiT22026actual→
Expected annual novel active substance launches (lower bound) +1 more Global2026–203070IQVIA2030forecast→
- United States2026–203050IQVIA2030forecast→
Expected annual novel active substance launches (upper bound) +1 more Global2026–203080IQVIA2030forecast→
- United States2026–203055IQVIA2030forecast→
Expected cumulative novel active substance launches (lower bound)Global2026–2030350IQVIA2030forecast→
Expected cumulative novel active substance launches (upper bound)Global2026–2030400IQVIA2030forecast→
First global drug approvalsChina202561DIAT22025actual→
First-cycle novel drug approvalsUnited States202437FDAT12024actual→
First-in-class drug approvals +8 more China202511NHSAT12025actual→
First-in-class novel active substance launches +1 more Global202530IQVIA2025actual→
First-year new prescriptions for novel medicines (multi-year total)United States2020–20247 millionIQVIA2024actual→
Five-year cumulative medicine use growthUnited States2020–202513%IQVIA2025actual→
Five-year cumulative novel active substance launches excluding COVID-19Global2021–2025369IQVIA2025actual→
Forecast list-price medicine spending growth lower boundUnited States2026–20306%IQVIA2030forecast→
Forecast list-price medicine spending growth upper boundUnited States2026–20309%IQVIA2030forecast→
Forecast net medicine spending growth lower boundUnited States2026–20304.5%IQVIA2030forecast→
Forecast net medicine spending growth upper boundUnited States2026–20307.5%IQVIA2030forecast→
Free cash flow +1 more GlobalQ2 20262,670 million EURSanofiT22026actual→
Free cash flow (half year)Globalas of 30 Jun 20263,724 million EURSanofiT22026actual→
Free cash flow growth +1 more GlobalQ2 202686.8%SanofiT22026actual→
Free cash flow growth (half year)Globalas of 30 Jun 202651.5%SanofiT22026actual→
Fusion protein approvalsChina20253DIAT22025actual→
General medicines sales growth (quarterly)GlobalQ2 2026-9%GSKT22026actual→
General medicines sales revenue (quarterly)GlobalQ2 20262.3 billion GBPGSKT22026actual→
Generic medicines receiving positive opinion (monthly)European UnionJuly 20263EMAT12026actual→
Genetically engineered share of new medicine launchesGermany202541%VFAT22025actual→
GIP/GLP-1 agonist spending growth contributionUnited States202514 billion USDIQVIA2025actual→
Group salesGlobalQ1 202630.4 billion CHFRocheT22026actual→
Group sales growth at constant exchange ratesGlobalQ1 20266%RocheT22026actual→
Group sales growth in Swiss francsGlobalQ1 2026-2%RocheT22026actual→
Group sales growth in US dollarsGlobalQ1 20268%RocheT22026actual→
Growth in cancer medicine spendingGlobal2019–202475%IQVIA2024actual→
Health sector research and development investment growth rate +3 more European Union202413%European CommissionT12025actual→
- China20240.1%European CommissionT12025actual→
- Japan20249.1%European CommissionT12025actual→
- United States20247.1%European CommissionT12025actual→
High GDP developed countries medicine spending growthGlobal2025–2030155.1 billion USDIQVIA2030forecast→
HIV medicines sales growth (quarterly)GlobalQ2 202610%GSKT22026actual→
HIV medicines sales revenue (quarterly)GlobalQ2 20262.1 billion GBPGSKT22026actual→
Human medicines recommended for marketing authorizationEuropean Union2025104EMAT12025actual→
Human medicines recommended for marketing authorization with new active substanceEuropean Union202538EMAT12025actual→
Human rare disease medicines recommended for marketing authorisationEuropean Union202516EMAT12025actual→
IFRS diluted earnings per share growth in Swiss francsGlobalQ1 2026-8%RocheT22026actual→
IFRS earnings per share +1 more GlobalQ2 20260.29 EURSanofiT22026actual→
IFRS earnings per share (half year)Globalas of 30 Jun 20261.63 EURSanofiT22026actual→
IFRS earnings per share growth +1 more GlobalQ2 2026-91%SanofiT22026actual→
IFRS earnings per share growth (half year)Globalas of 30 Jun 2026-65.6%SanofiT22026actual→
IFRS net income +1 more GlobalQ2 2026343 million EURSanofiT22026actual→
IFRS net income (half year)Globalas of 30 Jun 20261,957 million EURSanofiT22026actual→
IFRS net income growth +1 more GlobalQ2 2026-91.3%SanofiT22026actual→
IFRS net income growth (half year)Globalas of 30 Jun 2026-66.3%SanofiT22026actual→
IFRS operating profit +1 more GlobalQ1 20269.7 billion CHFRocheT22026actual→
IFRS operating profit (half year)Globalas of 30 Jun 20269,671 million CHFRocheT22026actual→
IFRS operating profit growth at constant exchange ratesGlobalQ1 20266%RocheT22026actual→
IFRS operating profit growth in Swiss francsGlobalQ1 2026-6%RocheT22026actual→
Imported drug approvalsChina202557DIAT22025actual→
Imported drug share of approvalsChina202548%DIAT22025actual→
Imported innovative biological product approvals +1 more China20252NHSAT12025actual→
Imported innovative chemical drug approvals +1 more China20259NHSAT12025actual→
Influenza casesGlobal20261 billionGSKT22026estimate→
Influenza deathsGlobal2026650,000GSKT22026estimate→
Innovative biological product approvals +1 more China202523NHSAT12025actual→
Innovative biological product approvals (half year)Chinaas of 30 Jun 202617NHSAT12026actual→
Innovative chemical drug approvals +1 more China202547NHSAT12025actual→
Innovative chemical drug approvals (half year)Chinaas of 30 Jun 202620NHSAT12026actual→
Innovative drug approvals +4 more China202576NHSAT12025actual→
Innovative drug approvals (half year) +1 more Chinaas of 30 Jun 202638State CouncilT12026actual→
Innovative drug approvals (year to date)Chinaas of 15 Apr 202614NHSAT12026actual→
Innovative drug licensing-out upfront payment valueChina202570 billion USDMOFCOMT12025actual→
Innovative drug negotiation success rateChina202490%State CouncilT12024actual→
Innovative drug out-licensing deal count +3 more China2025150NHSAT12025actual→
Innovative drug out-licensing deal count (half year)Chinaas of 30 Jun 202681NHSAT12026actual→
Innovative drug out-licensing deal value +4 more China20251,300 billion USDNHSAT12025actual→
Innovative drug out-licensing deal value (half year) +3 more Chinaas of 30 Jun 2026100 billion USDState CouncilT12026actual→
Innovative drugs added to national health insurance catalog +1 more Chinaas of 7 Dec 202550SCIOT12025actual→
- Chinaas of 7 Dec 202550State CouncilT12025actual→
Innovative drugs added to national health insurance drug listChinaas of 4 Sep 2026199State CouncilT12026actual→
Innovative drugs approved via priority review pathway +1 more China202417State CouncilT12024actual→
Innovative drugs granted conditional market approval +1 more China202411State CouncilT12024actual→
Innovative medicines spending target share of GDPUnited Kingdomas of 8 Sep 20260.6%ABPIT22026forecast→
Innovative traditional medicine approvals +1 more China20256NHSAT12025actual→
Innovative traditional medicine approvals (half year)Chinaas of 30 Jun 20261NHSAT12026actual→
Inter-trial interval increaseGlobal20253 monthsIQVIA2025actual→
Interchangeable biosimilar approvalsUnited States20249FDAT12024actual→
International multi-center clinical trialsChina2025410NHSAT12025actual→
International multi-center clinical trials shareChina202513.7%NHSAT12025actual→
Jurisdiction share of regional clinical trialsIndiaas of 30 Jun 202585%WHOT12025actual→
Jurisdiction share of total clinical trialsIndiaas of 30 Jun 202510%WHOT12025estimate→
Label extensions for approved medicinesGermany202520VFAT22025actual→
Large company small molecule share of Phase I clinical trial starts +3 more Global202566%IQVIA2025actual→
Life sciences and patient organization deal valueUnited Statesas of 5 Oct 20232.4 billion USDIQVIA2023estimate→
Life sciences and patient organization dealsUnited Statesas of 5 Oct 2023700IQVIA2023estimate→
Life sciences employmentUnited Kingdomas of 28 Jul 202622,000GSKT22026actual→
Long-term annual sales outlookGlobal203140 billion GBPGSKT22031forecast→
Median drug approval time +1 more Canada2025369 daysCIRS2025actual→
- Switzerland2025413 daysCIRS2025actual→
Median drug approval time (count) +1 more United Kingdom2025378ABPIT22025actual→
- United Kingdom2024427ABPIT22024actual→
Medicare patient out-of-pocket medicine cost declineUnited States2025638 million USDIQVIA2025actual→
Medicine spending +1 more Global20231.6 trillion USDIQVIA2023actual→
Medicine spending growth rate lower boundGlobal2026–20305%IQVIA2030forecast→
Medicine spending growth rate upper boundGlobal2026–20308%IQVIA2030forecast→
Medicine use compound annual growth rate +1 more Global2026–20302.7%IQVIA2030forecast→
Medicines added to national health insurance drug listChinaas of 4 Sep 2026949State CouncilT12026actual→
Medicines in clinical development +1 more Global202512,900IFPMAT22025actual→
Medicines recommended for marketing authorisationEuropean Union202289EMAT12022actual→
Medicines with new active substances recommended for marketing authorisationEuropean Union202242EMAT12022actual→
Monoclonal antibody approvalsChina202518DIAT22025actual→
Monoclonal antibody share of new drug approvalsChina202515%DIAT22025actual→
Multi-country oncology clinical trial starts +2 more Global2024403IQVIA2024actual→
Multi-country share of oncology clinical trial starts +1 more Global202420%IQVIA2024actual→
Negotiated or bid drugs added to national reimbursement drug listChinaas of 28 Nov 202489NHSAT12024actual→
Negotiated or bid drugs added to national reimbursement drug list (annual)China202489State CouncilT12024actual→
Negotiated pharmaceutical sales driven by medical insuranceChinaas of 28 Feb 2026740 billion CNYNHSAT12026actual→
Net medicine spending +1 more United States2025606 billion USDIQVIA2025actual→
- United States2024548 billion USDIQVIA2024actual→
Net medicine spending growthUnited States202510.6%IQVIA2025actual→
Net medicine spending increaseUnited States202558 billion USDIQVIA2025actual→
New active substance approvals +1 more Canada202544CIRS2025actual→
- Switzerland202534CIRS2025actual→
New drug clinical trial initiation time reductionChina20254 monthsNHSAT12025actual→
New drug clinical trials growth rateChina202518%NHSAT12025actual→
New drug clinical trials share +1 more China202557.5%NHSAT12025actual→
New medicines availability rateUnited Kingdom2021–202433%ABPIT22024actual→
New medicines launched with orphan drug designationGermany202514VFAT22025actual→
New medicines recommended for approval (monthly)European UnionJuly 202612EMAT12026actual→
New rare disease drug launchesGermany202525VFAT22025actual→
Newer medicines clawback rateUnited Kingdom202522.9%ABPIT22025actual→
Newly added drugs in national reimbursement drug list +2 more Chinaas of 7 Dec 2025114SCIOT12025actual→
Newly added drugs in national reimbursement drug list (annual) +1 more China2025114NHSAT12025actual→
- China202491State CouncilT12024actual→
Non-retail share of prescription medicine useUnited States202516%IQVIA2025actual→
Novel active substance launches +6 more Global202579IQVIA2025actual→
Novel active substance launches (multi-year total) +1 more United States2021–2025270IQVIA2025actual→
- United States2020–202499IQVIA2024actual→
Novel active substance launches growth rate +1 more United States2021–202517%IQVIA2025actual→
- United States2021–202517%IQVIA2025actual→
Novel antibiotic approvalsUnited States20243FDAT12024actual→
Novel drug approvals +2 more United States202546FDAT12025actual→
- United States202450FDAT12024actual→
- United States202450FDAT12024actual→
Novel drug approvals meeting user fee goal datesUnited States202447FDAT12024actual→
Novel drug approvals using expedited programsUnited States202433FDAT12024actual→
Novel drug approvals via priority review pathwayChina202417NMPAT12024actual→
Novel drugs approved first in domestic marketUnited States202434FDAT12024actual→
Novel drugs granted conditional market approvalChina202411NMPAT12024actual→
Novel medicine prescription fill rateUnited States2020–202435%IQVIA2024actual→
Novel medicine prescription patient abandonment rateUnited States2020–202417%IQVIA2024actual→
Novel medicine prescription payer rejection rateUnited States2020–202449%IQVIA2024actual→
Novel medicine prescription unfilled rateUnited States2020–202465%IQVIA2024actual→
Novel modalities share of oncology clinical trialsGlobal202435%IQVIA2024actual→
Obesity-approved GIP and GLP-1 agonist medicine spending growthUnited States20259.6 billion USDIQVIA2025actual→
Off-catalog drugs participating in price negotiation or biddingChinaas of 28 Nov 2024117NHSAT12024actual→
Off-patent products salesGlobalQ1 20262.6 billion CHFRocheT22026actual→
Oncology clinical development productivity growthGlobal2019–202451%IQVIA2024actual→
Oncology clinical trial startsGlobal20242,162IQVIA2024actual→
Oncology clinical trial starts growth rate +3 more Global2024–2025-4%IQVIA2025actual→
Oncology novel active substance launchesGlobal202425IQVIA2024actual→
Oncology novel active substance launches (multi-year total) +2 more China2020–202484IQVIA2024actual→
Oncology sales growth (quarterly)GlobalQ2 202617%GSKT22026actual→
Oncology sales revenue (quarterly)GlobalQ2 20260.6 billion GBPGSKT22026actual→
Oncology share of all clinical trialsGlobal202441%IQVIA2024actual→
Operating profit growth (quarterly)GlobalQ2 2026-75%GSKT22026actual→
Orphan drug approvalsUnited States202426FDAT12024actual→
Patient organization donor share in life sciences dealsGlobalas of 5 Oct 202375%IQVIA2023actual→
Patient organization input share in drug health technology assessments +1 more Globalas of 5 Oct 202321%IQVIA2023actual→
- European Unionas of 5 Oct 202352%IQVIA2023actual→
Patient out-of-pocket medicine cost increaseUnited States20256 billion USDIQVIA2025actual→
Patient out-of-pocket medicine costsUnited States2025110 billion USDIQVIA2025actual→
Patients treated with drugGlobalas of 10 Sep 202610,000RocheT22026actual→
Pediatric medicine approvals +2 more China2024106NMPAT12024actual→
Peptide therapy approvalsChina20254DIAT22025actual→
Per capita medicine use compound annual growth rate +4 more North America2020–20252.1%IQVIA2025actual→
Pharmaceutical and life sciences R&D facility investmentUnited Kingdomas of 28 Jul 2026400 million GBPGSKT22026estimate→
Pharmaceutical and life sciences R&D facility investment (annual)United Kingdom2026–2029400 million GBPGSKT22029forecast→
Pharmaceutical and medicine manufacturing company-funded R&DUnited States2023114,225 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing externally funded R&DUnited States202311,761 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing government-funded R&DUnited States2023549 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing net salesUnited States2022685,744 million USDNCSEST12022actual→
Pharmaceutical and medicine manufacturing R&D funded by domestic companiesUnited States20232,104 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D funded by foreign companiesUnited States20239 billion USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D funded by other external sourcesUnited States202379 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D intensity +1 more United States202317.8%NCSEST12023actual→
- United States202217%NCSEST12022actual→
Pharmaceutical and medicine manufacturing total R&D performance +1 more United States2023125,986 million USDNCSEST12023actual→
- United States2022116,073 million USDNCSEST12022actual→
Pharmaceutical business enterprise research and development expenditureUnited Kingdom20238.7 billion GBPONST12023actual→
Pharmaceutical corporate employmentUnited Statesas of 20 Aug 202625,000RocheT22026estimate→
Pharmaceutical direct gross value addedUnited Kingdomas of 8 Sep 202620.4 billion GBPABPIT22026actual→
Pharmaceutical export delivery value growth (half year) +1 more Chinaas of 30 Jun 20269%State CouncilT12026actual→
Pharmaceutical industry direct employmentGlobal20227.8 millionIFPMAT22022actual→
Pharmaceutical industry employmentUnited Kingdomas of 8 Sep 2026125,000ABPIT22026actual→
Pharmaceutical industry export delivery value (half year) +2 more Chinaas of 30 Jun 2026210 billion CNYState CouncilT12026actual→
Pharmaceutical industry investment commitmentsUnited Kingdom2025–20262 billion GBPABPIT22026actual→
Pharmaceutical industry R&D expenditure growth rateChina2021–202523%NHSAT12025actual→
Pharmaceutical industry total profit growth rateChina2021–202511.3%NHSAT12025actual→
Pharmaceutical launches salesGlobalQ2 20261.3 billion EURSanofiT22026actual→
Pharmaceutical launches sales (annual)Global203010 billion EURSanofiT22026forecast→
Pharmaceutical launches sales growthGlobalQ2 202648.3%SanofiT22026actual→
Pharmaceutical manufacturing employment +2 more Franceas of 14 Sep 202665SanofiT22026estimate→
Pharmaceutical manufacturing employment creation +1 more United Statesend of 2031250RocheT22026forecast→
- United Statesas of 20 Aug 2026250RocheT22026forecast→
Pharmaceutical manufacturing facility capital investmentUnited Statesas of 20 Aug 2026750 million USDRocheT22026forecast→
Pharmaceutical manufacturing sitesUnited Statesas of 20 Aug 202613RocheT22026actual→
Pharmaceutical marketing authorizationsGlobalas of 14 Sep 20263,440SanofiT22026actual→
Pharmaceutical R&D employmentGlobal20221 millionIFPMAT22022actual→
Pharmaceutical R&D GDP contributionGlobal2022227 billion USDIFPMAT22022actual→
Pharmaceutical research and development sitesUnited Statesas of 20 Aug 202615RocheT22026actual→
Pharmaceutical sales revenueGlobalQ2 20268.4 billion GBPGSKT22026actual→
Pharmaceutical share of business enterprise research and development expenditureUnited Kingdom202317.4%ONST12023actual→
Pharmaceutical value-added industrial output growth (half year) +1 more Chinaas of 30 Jun 20266.4%State CouncilT12026actual→
Pharmaceuticals division salesGlobalQ1 202623.6 billion CHFRocheT22026actual→
Pharmaceuticals division sales growth at constant exchange ratesGlobalQ1 20266%RocheT22026actual→
Pharmaceuticals division sales growth in Swiss francsGlobalQ1 2026-1%RocheT22026actual→
Pharmaceuticals division sales growth in US dollarsGlobalQ1 20268%RocheT22026actual→
Pharmerging markets medicine spending growth +2 more Global2020–2025118 billion USDIQVIA2025actual→
Phase I immunology clinical trial starts growth rate +1 more Global2024–2025-13%IQVIA2025actual→
Phase I share of oncology clinical trial startsGlobal202438%IQVIA2024actual→
Phase I small molecule clinical trial share +5 more Global202562%IQVIA2025actual→
Phase II immunology clinical trial starts growth rate +1 more Global2024–202514%IQVIA2025actual→
Phase II oncology clinical trial starts growth rate +1 more Global2024–20253%IQVIA2025actual→
Phase II share of oncology clinical trial startsGlobal202448%IQVIA2024actual→
Phase III clinical trial starts (annual)Global202620GSKT22026forecast→
Phase III immunology clinical trial starts growth rate +1 more Global2024–2025-4%IQVIA2025actual→
Phase III oncology clinical trial starts growth rate +1 more Global2024–20254%IQVIA2025actual→
Phase III share of oncology clinical trial startsGlobal202414%IQVIA2024actual→
Prescription medicine useUnited States2025210 billion days of therapyIQVIA2025actual→
Prescription medicine use growthUnited States20251.5%IQVIA2025actual→
Priority review drug approval applications completed growth rate +1 more China202429%State CouncilT12024actual→
Projected net medicine spending increaseUnited States2025–2030200 billion USDIQVIA2030forecast→
Projected patient out-of-pocket burden reductionChina202550 billion CNYState CouncilT12025forecast→
Projected pharmaceutical direct gross value addedUnited Kingdom203533.4 billion GBPABPIT22035forecast→
Projected pharmaceutical employmentUnited Kingdom2035200,000ABPIT22035forecast→
Projected pharmaceutical job creationUnited Kingdomend of 203581,300ABPIT22035forecast→
R&D share of pharmaceutical direct economic contributionGlobal202230%IFPMAT22022actual→
Radiopharmaceutical market sizeChina203026 billion CNYNHSAT12030forecast→
Rare cancer share of oncology clinical trial startsGlobal202474%IQVIA2024actual→
Rare disease drug varieties approvedChina202439State CouncilT12024actual→
Rare disease medicine approvals +2 more China202455NMPAT12024actual→
Rare diseases treatment availability rateGlobalend of 20255%PhRMAT22025estimate→
Reference products with biosimilar approvalsUnited States20248FDAT12024actual→
Reimbursement drug list conventional medicinesChinaas of 28 Nov 20241,765NHSAT12024actual→
Reimbursement drug list conventional medicines (annual)China20251,857NHSAT12025actual→
Reimbursement drug list total drugs +3 more Chinaas of 7 Dec 20253,253SCIOT12025actual→
- Chinaas of 7 Dec 20253,253State CouncilT12025actual→
- Chinaas of 28 Nov 20243,159NHSAT12024actual→
- Chinaas of 28 Nov 20243,159State CouncilT12024actual→
Reimbursement drug list total drugs (annual)China20253,253NHSAT12025actual→
Reimbursement drug list traditional patent medicinesChinaas of 28 Nov 20241,394NHSAT12024actual→
Reimbursement drug list traditional patent medicines (annual)China20251,396NHSAT12025actual→
Research and development expensesGlobalQ2 20262.2 billion EURSanofiT22026actual→
Research and development expenses growthGlobalQ2 202617.9%SanofiT22026actual→
Respiratory immunology and inflammation sales growth (quarterly)GlobalQ2 202619%GSKT22026actual→
Respiratory immunology and inflammation sales revenue (quarterly)GlobalQ2 20261.1 billion GBPGSKT22026actual→
Retail prescription drug volume compound annual growth rateUnited States2020–20252.4%IQVIA2025actual→
Retail share of prescription medicine useUnited States202584%IQVIA2025actual→
Retrospective clinical trial registration rateAsia-Pacific202416%WHOT12024actual→
Retrospectively registered clinical trialsAsia-Pacific20245,326WHOT12024actual→
Reusable contact lens share of wearersGlobalas of 10 Sep 202650%J&JT22026actual→
Sales growth at actual exchange rates (quarterly)GlobalQ2 20265%GSKT22026actual→
Sales growth at constant exchange rates +8 more GlobalQ2 202617.8%SanofiT22026actual→
- GlobalQ1 20263%RocheT22026actual→
- European UnionQ1 20261%RocheT22026actual→
- Asia-PacificQ1 2026-5%RocheT22026actual→
- Latin America and the CaribbeanQ1 202610%RocheT22026actual→
- North AmericaQ1 20268%RocheT22026actual→
- ChinaQ1 2026-9%RocheT22026actual→
- JapanQ1 202611%RocheT22026actual→
- United StatesQ1 20266%RocheT22026actual→
Sales growth at constant exchange rates (annual)Global202610%SanofiT22026forecast→
Sales growth at constant exchange rates (quarterly)GlobalQ2 20265%GSKT22026actual→
Sales growth in Swiss francs +7 more GlobalQ1 2026-1%RocheT22026actual→
- European UnionQ1 2026-1%RocheT22026actual→
- Asia-PacificQ1 2026-12%RocheT22026actual→
- Latin America and the CaribbeanQ1 20265%RocheT22026actual→
- North AmericaQ1 2026-1%RocheT22026actual→
- ChinaQ1 2026-12%RocheT22026actual→
- JapanQ1 2026-5%RocheT22026actual→
- United StatesQ1 2026-3%RocheT22026actual→
Selling and general expensesGlobalQ2 20262.5 billion EURSanofiT22026actual→
Selling and general expenses growthGlobalQ2 20269%SanofiT22026actual→
Severe influenza casesGlobal20265 millionGSKT22026estimate→
Share of clinical development medicines dedicated to non-communicable diseasesGlobal202575%IFPMAT22025actual→
Share of first-cycle novel drug approvalsUnited States202474%FDAT12024actual→
Share of global biopharmaceutical licensing dealsChina202520%State CouncilT12025actual→
Share of global biopharmaceutical pipeline +1 more China202530%State CouncilT12025actual→
- China20152%State CouncilT12015actual→
Share of global biopharmaceutical pipeline (snapshot)Chinaas of 30 Jun 202630%NHSAT12026actual→
Share of high-value-added products in pharmaceutical exports (half year)Chinaas of 30 Jun 202620%MOFCOMT12026actual→
Share of medicine spending growthGlobal2025–203076%IQVIA2030forecast→
Share of novel drug approvals meeting user fee goal datesUnited States202494%FDAT12024actual→
Share of novel drug approvals using expedited programsUnited States202466%FDAT12024actual→
Share of novel drugs approved first in domestic marketUnited States202468%FDAT12024actual→
Share of priority review drug approval applications treating cancerChinaend of 202442.5%State CouncilT12024actual→
Share of priority review drug approval applications treating cancer (annual)China2020–202442.5%NMPAT12024actual→
Small molecule drug approvalsChina202572DIAT22025actual→
Small molecule share of new drug approvalsChina202560%DIAT22025actual→
Specialty medicines sales growth (quarterly)GlobalQ2 202614%GSKT22026actual→
Specialty medicines sales revenue (quarterly)GlobalQ2 20263.8 billion GBPGSKT22026actual→
Successful price negotiations or bids for off-catalog drugsChinaas of 28 Nov 202489NHSAT12024actual→
T-cell engager market size for multiple myelomaUnited States203210 billion USDGSKT22032forecast→
Tiered countries share of clinical trial country usesGlobal2021–202319%IQVIA2023actual→
Top 20 biological targets research and development project concentrationChina202541%MOFCOMT12025actual→
Top 50 global pharmaceutical companies countChinaas of 15 Apr 20266NHSAT12026actual→
Top countries share of clinical trial pipeline useGlobal2021–202358%IQVIA2023actual→
Top countries share of medicine spending growthGlobal2026–203083%IQVIA2030forecast→
Top growth drivers salesGlobalQ1 202611 billion CHFRocheT22026actual→
Total medicine usageGlobal20304 trillion defined daily dosesIQVIA2030forecast→
Type 2 diabetes drug launchesChina20256DIAT22025actual→
Unfilled prescription rate across all brands and branded genericsUnited States202529%IQVIA2025actual→
Vaccines salesGlobalQ2 20261.1 billion EURSanofiT22026actual→
Vaccines sales growthGlobalQ2 2026-4.7%SanofiT22026actual→
Vaccines sales growth (quarterly)GlobalQ2 20268%GSKT22026actual→
Vaccines sales revenue (quarterly)GlobalQ2 20262.3 billion GBPGSKT22026actual→
Primary documents
Sources
The complete list of documents behind this page. Nothing is hidden and nothing is behind a disclosure.
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| The 2025 EU Industrial R&D Investment Scoreboard Press release | European Commission | T1 Official | 22 Dec 2025 | 17 Sep 2026 | EU: Health and energy sectors shine in a year of slowdown | 4 |
| Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026 Press release | EMA | T1 Official | — | 15 Sep 2026 | Twelve new medicines recommended for approval | 2 |
| EMA’s 2025 annual report shows strong approval numbers for human and veterinary medicines Press release | EMA | T1 Official | — | 17 Sep 2026 | EMA’s 2025 annual report shows strong approval numbers for human and veterinary medicines | 3 |
| Human medicines: highlights of 2022 Press release | EMA | T1 Official | — | 17 Sep 2026 | Update as of 3 March 2026 | 2 |
| 2025年我国批准创新药76个 对外授权超千亿美元 Press release | MOFCOM | T1 Official | — | 17 Sep 2026 | 2025年我国批准创新药76个 对外授权超千亿美元 | 20 |
| 上半年我国创新药对外技术授权交易额创新高 Press release | MOFCOM | T1 Official | — | 17 Sep 2026 | 上半年我国创新药对外技术授权交易额创新高 | 7 |
| Business R&D Performance in the United States Increases to $722 Billion in 2023 Press release | NCSES | T1 Official | — | 17 Sep 2026 | Table 2. Funds spent for business R&D performed in the United States, by source of funds, selected industry, and company size: 2023; R&D Performance, by Type of R&D, Industry Sector, and Source of Funding; Sales, R&D Intensity, and Employment of Companies That Performed or Funded R&D | 8 |
| Discovery: R&D Activity and Research Publications Press release | NCSES | T1 Official | — | 17 Sep 2026 | Industries That Perform the Most U.S. Business R&D; Table DISC-3. Domestic net sales, R&D, and R&D-to-sales ratio for companies that performed or funded U.S. business R&D, by selected industry: 2022 | 3 |
| 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 Press release | NHSA | T1 Official | 28 Nov 2024 | 17 Sep 2026 | 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 | 14 |
| 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 大众新闻大众日报记者提问; 红星新闻记者提问; 经济日报记者提问 | 7 |
| 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产; 我国上半年创新药对外授权约1100亿美元 创历史新高; 11款新靶点新机制创新药涵盖哪些治疗领域 | 14 |
| 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 试验包括新药临床试验和生物等效性试验; 新药临床试验近六成 其中超七成是创新药; 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 | 14 |
| 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 | 7 |
| 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元 Press release | NHSA | T1 Official | — | 17 Sep 2026 | 创新高！去年我国批准创新药76个 对外授权破千亿美元 | 17 |
| Measures facilitate approval of 48 first-in-class innovative drugs Press release | NMPA | T1 Official | — | 17 Sep 2026 | Measures facilitate approval of 48 first-in-class innovative drugs | 13 |
| China approves 48 innovative drugs in 2024 Press release | NMPA | T1 Official | — | 17 Sep 2026 | China approves 48 innovative drugs in 2024 | 6 |
| Business enterprise research and development, UK Press release | ONS | T1 Official | — | 17 Sep 2026 | Main points | 2 |
| China updates national medical insurance catalog, adds 114 new drugs Press release | SCIO | T1 Official | — | 17 Sep 2026 | China updates national medical insurance catalog, adds 114 new drugs | 4 |
| Measures facilitate approval of 48 first-in-class innovative drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | Measures facilitate approval of 48 first-in-class innovative drugs | 12 |
| 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网 Press release | State Council | T1 Official | — | 17 Sep 2026 | 7年累计将835种药品新增进入目录; 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药; “全球新”的创新药有38种，创历年新高 | 10 |
| China scales up support for clinical trials, accelerating drug development Press release | State Council | T1 Official | — | 17 Sep 2026 | China scales up support for clinical trials, accelerating drug development | 3 |
| Value of China's innovative drug out-licensing deals hit new high in H1 Press release | State Council | T1 Official | — | 17 Sep 2026 | Value of China's innovative drug out-licensing deals hit new high in H1 | 7 |
| China updates national medical insurance catalog, adds 114 new drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | China updates national medical insurance catalog, adds 114 new drugs | 4 |
| 全面深化监管改革 缩短临床试验审评审批时限——加快创新药和医疗器械上市_政策解读_中国政府网 Press release | State Council | T1 Official | — | 17 Sep 2026 | 大力支持产业创新; 更好满足临床急需 | 2 |
| China to expand health insurance coverage for innovative drugs Press release | State Council | T1 Official | — | 17 Sep 2026 | China to expand health insurance coverage for innovative drugs | 6 |
| CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 Press release | FDA | T1 Official | — | 17 Sep 2026 | A Record Year for Biosimilar Approvals; CDER’s Effectiveness Bringing New Therapies to Market; Creating a Yearly Snapshot for Approvals | 15 |
| FDA Seeks Public Input to Advance Development of Botanical Drug Products Press release | FDA | T1 Official | — | 17 Sep 2026 | FDA Seeks Public Input to Advance Development of Botanical Drug Products | 1 |
| Novel Drug Approvals for 2025 Press release | FDA | T1 Official | — | 17 Sep 2026 | FDA Novel Drug Therapy Approvals for 2025 | 1 |
| Novel Drug Approvals for 2024 Press release | FDA | T1 Official | — | 17 Sep 2026 | FDA Novel Drug Therapy Approvals for 2024 | 1 |
| Number of clinical trials by year, country, WHO region and income group (1999-2022) Press release | WHO | T1 Official | — | 17 Sep 2026 | Points to note: | 7 |
| Green shoots for UK pharma investment, but delivery will decide whether they take root Press release | ABPI | T2 National | — | 17 Sep 2026 | UK competitive weaknesses; UK areas of unrealised potential; Green shoots for UK pharma investment, but delivery will decide whether they take root | 15 |
| 2025 NMPA Approvals: China Clears Record Number of New Drugs Press release | DIA | T2 National | — | 17 Sep 2026 | Established Modalities Maintain a Larger Presence; 2025 NMPA Approvals: China Clears Record Number of New Drugs; The Cancer Sector Continues to Attract the Most Players | 20 |
| GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK Press release | GSK | T2 National | — | 17 Sep 2026 | GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK | 4 |
| GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026 Press release | GSK | T2 National | — | 17 Sep 2026 | R&D acceleration:; Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth; Growth outlooks: | 20 |
| GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data Press release | GSK | T2 National | — | 15 Sep 2026 | About seasonal flu | 3 |
| GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences Press release | GSK | T2 National | — | 15 Sep 2026 | Deal aligned to GSK’s portfolio in blood cancer and approach of acquiring differentiated assets with validated targets | 1 |
| Enabling innovation: The R&D ecosystem for medicines and vaccines Press release | IFPMA | T2 National | — | 15 Sep 2026 | Enabling innovation: The R&D ecosystem for medicines and vaccines | 7 |
| Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses Press release | J&J | T2 National | — | 17 Sep 2026 | Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses | 2 |
| Research & Development Press release | PhRMA | T2 National | — | 17 Sep 2026 | Revolutionizing Cancer Care with Immunotherapy; Progress toward New Medicines and Vaccines; Policy Framework | 7 |
| U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments Press release | Roche | T2 National | 10 Sep 2026 | 15 Sep 2026 | About Enspryng (satralizumab) | 2 |
| Roche’s US subsidiary Genentech announces manufacturing expansion in the United States Press release | Roche | T2 National | 20 Aug 2026 | 15 Sep 2026 | About Roche; Roche’s US subsidiary Genentech announces manufacturing expansion in the United States | 8 |
| [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a... Press release | Roche | T2 National | 23 Jul 2026 | 15 Sep 2026 | Key figures CHF millions % change; [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc; Group results | 43 |
| Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines Press release | Sanofi | T2 National | 14 Sep 2026 | 15 Sep 2026 | Sanofi and Cheplapharm to create new strategic partnership in mature medicines; About Cheplapharm | 4 |
| Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded Press release | Sanofi | T2 National | 30 Jul 2026 | 15 Sep 2026 | Guidance upgraded; Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded; Belén Garijo, Chief Executive Officer | 36 |
| Neue Medikamente in Deutschland: Innovationsbilanz 2025 Press release | VFA | T2 National | — | 17 Sep 2026 | Herstellungsarten; Innovationsbilanz 2025; Medikamente gegen seltene Erkrankungen | 6 |
| New Drug Approvals by Six Major Authorities 2016-2025 Press release | CIRS | T3 Research | — | 17 Sep 2026 | Key Findings | 6 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025; Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025; The number of novel active substance (NAS) launches increased on a global basis | 24 |
| Global Oncology Trends 2025 Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Other Findings; Key Findings: Oncology continues to see significant novel medicine launches; Key Findings: Spending on oncology medicines is growing across geographies and tumors | 29 |
| U.S. Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Other Findings; Key Findings | 34 |
| Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Cell and gene therapy clinical trial starts by type, 2013-2023; Status of cell and gene therapy reimbursement in Europe (Apr 2023) compared to GDP per capital 2022, current international dollars PPP; Key findings | 21 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025; Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025; Key Findings | 24 |
| Rethinking Clinical Trial Country Prioritization Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Key findings:; Country utilization is heavily consolidated in U.S., China and Western European countries; Enrollment is taking longer across all phases of development | 15 |
| Global Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 20: High growth developed and Pharmerging markets spending and growth,constant US$, 2015–2030; Exhibit 15: Global medicine market size and growth including estimated COVID-19 vaccine and therapeutic spending, 2016–2030; Report Summary: | 19 |
| Supporting patients through research collaboration Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Key findings:; Three quarters of all deals find patient organizations in the role of donor, providing grants or use of intellectual property to life sciences companies, but collaborative research is decreasing.; Patient organizations now provide input into 21% of all drug health technology assessments (HTAs) globally and up to 52% in some therapy areas in EU and Commonwealth countries. | 5 |
| IQVIA Institute’s Global R&D Trends 2026 Report Finds Credible Signal on AI-Enabled Programs Press release | IQVIA | T3 Research | — | 17 Sep 2026 | IQVIA Institute’s Global R&D Trends 2026 Report Finds Credible Signal on AI-Enabled Programs | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 572 collected records are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it.
StatOrigin. (2026). Pharmaceuticals Industry Statistics. Retrieved from https://statorigin.org/industries/pharmaceuticals
Found an error? Every figure here is checkable against its
source, and we would rather be corrected than be wrong. Report a problem; we
respond within 48 hours, and corrections are logged publicly on the corrections page.
This page was last generated on 17 September 2026 from a verified dataset snapshot. It is rebuilt whenever the underlying data changes.